

Annual General Meeting of BioGaia

The Annual General Meeting of BioGaia AB on 26 April 2013 voted to approve the following resolutions:

- a dividend of SEK 10.00 per share
- re-election of Board members Jan Annwall, Stefan Elving, Thomas Flinck, David Dangoor, Inger Holmström, Jörgen Thorball and Paula Zeilon
- re-election of David Dangoor as Board Chairman
- payment of Board member compensation in an amount of SEK 300,000 to the Chairman and SEK 150,000 to each of the other Board members not employed by the company
- auditors' fee shall be paid according to approved account
- regarding principles for remuneration and other terms of employment for senior executives in accordance with the Board's proposal
- regarding the Nominating Committee in accordance with the Nominating Committee's proposal

All decisions that were passed by the Annual General Meeting are consistent with the Board's and Nominating Committee's previously published proposals.

For additional information please contact

Peter Rothschild, President, telephone: +46 8 555 293 00

Margareta Hagman, Executive Vice President, telephone: +46 8 555 293 00

Latest press releases from BioGaia

2013-04-26	BioGaia AB Interim report 1 January – 31 March 2013
2013-03-21	Notice to attend the Annual General Meeting of BioGaia AB
2013-02-08	BioGaia AB Year-end report 2012

BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 26 April, 2013 4:00 pm CET.

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium *Lactobacillus reuteri* which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com